Smoking and smoking cessation in pregnancy

Smoking during pregnancy is among the leading preventable causes of adverse maternal and fetal outcomes. Smoking prevalence among young women is the primary determinant of smoking prevalence during pregnancy. Smoking among women of childbearing age is associated with reduced fertility, increased complications of pregnancy, and a variety of adverse fetal outcomes. There is increasing evidence of lasting adverse effects on offspring. Guidelines for smoking cessation during pregnancy have been developed. This article reviews the epidemiology of smoking during pregnancy, the adverse effects of smoking on the mother, fetus, and offspring, and recommended approaches to smoking cessation for pregnant women.     

Smoking cessation strategies in pregnancy: Current concepts and controversies

Smoking during pregnancy is a risk factor associated with adverse pregnancy outcomes. Despite the fact that these outcomes are well known, a considerable proportion of pregnant women continue to smoke during this critical period. This paper evaluates critically smoking cessation interventions targeting pregnant women. We describe the findings of key published studies, review papers and expert statements to report the efficacy and safety of strategies for smoking cessation in pregnancy, including counselling and pharmacotherapy. Counselling appears to improve quit rates but mainly when used in combination with pharmacological therapy. Pharmacotherapy is recommended for women who are heavy smokers and are unable to quit smoking on their own. Nicotine replacement therapy is a reasonable first-line drug option. It is recommended that women who are pregnant, or planning to become pregnant, should be informed of potential risks for the foetus before considering smoking cessation therapy with bupropion or varenicline. Pregnant women view electronic nicotine delivery systems as being safer than combustible cigarettes, and this indeed may be the case; however, further evidence is required to assess their effectiveness as a smoking cessation aid and their safety for the mother and the child. Postpartum relapse is a significant problem, with approximately one out of two quitters relapsing in the first 2 months after delivery. These women should be considered ‘at risk’ and provided with ongoing support.     

Smoking cessation or reduction in pregnancy treatment methods: a meta-evaluation of the impact of dissemination

Active and passive exposure to tobacco smoke during pregnancy and infancy is the most serious and preventable cause of adverse maternal, fetal, and infant outcomes in the United States. The multiple risks of tobacco exposure to mothers and infants are definitive, and the clinical and economic benefits of cessation have been documented. This article provides a synopsis of the state of the science and art in this specialized area and reviews the evidence for validity of patient assessment methods and the effectiveness of smoking cessation/reduction treatments for pregnant women. A synthesis of 4 topics is presented: (1) the validity of patient reports of smoking status and recent trends during pregnancy and postpartum; (2) definition of "Best Practice" smoking cessation methods for pregnant women; (3) the effect of dissemination of effective clinical practice methods among the 800,000+ pregnant US smokers each year; and (4) the evidence for the cost-benefit of improved maternal and infant outcomes from cessation.     

Associations between maternal stress and smoking: findings from a population-based prospective cohort study

Aims To investigate associations between maternal stress and smoking prior to, during and 6 months after the pregnancy. Design A prospective population‐based cohort study. Setting Norway. Participants A total of 71 757 women in the Norwegian Mother and Child Cohort Study (MoBa) participating twice during pregnancy and at 6 months postpartum. Measurements Respondents' estimates of anxiety and depression, relationship discord and negative life events were measured, along with self‐reports of smoking behaviour and demographic variables. Smoking was assessed at gestation weeks 17 and 30 and at 6 months postpartum. Findings Of the 27.5% women who smoked at conception, 55.8% quit smoking during pregnancy. At 6 months postpartum, 28.9% of quitters had relapsed to smoking. In total, 12.9% of the sample reported smoking during the pregnancy. Adjusted for well‐known risk factors, women reporting high levels of anxiety and depression had a decreased likelihood of quitting smoking during pregnancy [odds ratio (OR) 0.80, 95% confidence interval (CI): 0.73, 0.88) and an increased likelihood of relapsing after delivery (OR 1.26, 95% CI: 1.11, 1.44). Both relationship discord (OR 0.82, 95% CI: 0.75, 0.90) and exposure to negative life events (OR 0.93, 95%: CI 0.90, 0.96) had a negative influence on quitting smoking during pregnancy but had no influence on relapse to smoking postpartum. Conclusions Maternal stress and relationship discord may inhibit smoking cessation during pregnancy and promote resumption of smoking after pregnancy in women who have achieved abstinence.     

Tobacco Industry Research on Smoking Cessation

BACKGROUND:  Smoking rates are declining in the United States, except for young adults (age 18 to 24). Few organized programs target smoking cessation specifically for young adults, except programs for pregnant women. In contrast, the tobacco industry has invested much time and money studying young adult smoking patterns. Some of these data are now available in documents released through litigation.
OBJECTIVE:  Review tobacco industry marketing research on smoking cessation to guide new interventions and improve clinical practice, particularly to address young adult smokers' needs.
METHODS:  Analysis of previously secret tobacco industry documents.
RESULTS:  Compared to their share of the smoking population, young adult smokers have the highest spontaneous quitting rates. About 10% to 30% of smokers want to quit; light smokers and brand switchers are more likely to try. Tobacco companies attempted to deter quitting by developing products that appeared to be less addictive or more socially acceptable. Contrary to consumer expectations, "ultra low tar" cigarette smokers were actually less likely to quit.
CONCLUSIONS:  Tobacco industry views of young adult quitting behavior contrast with clinical practice. Tobacco marketers concentrate on recapturing young quitters, while organized smoking cessation programs are primarily used by older smokers. As young people have both the greatest propensity to quit and the greatest potential benefits from smoking cessation, targeted programs for young adults are needed. Tobacco marketing data suggest that aspirational messages that decrease the social acceptability of smoking and support smoke-free environments resonate best with young adult smokers' motivations.     

Models for Access to Maternal Smoking Cessation Support: a quasi-experiment to increase the engagement of pregnant women who smoke in National Health Service stop smoking services

BackgroundMaternal smoking is a key cause of poor health outcomes. In Wales, a third of pregnant women smoke before or during pregnancy, the highest prevalence of maternal smoking in the UK. Supporting women to stop smoking during pregnancy is a challenging area of public health. Models for Access to Maternal Smoking Cessation Support (MAMSS) aimed to examine the effectiveness of smoking cessation in pregnancy services delivered by specially trained practitioners.MethodsA non-randomised, quasi-experiment was undertaken across four Health Boards in Wales to assess the effectiveness of new models of service designed to increase the engagement of pregnant women in National Health Service (NHS) stop smoking services. Qualitative approaches were adopted to capture important contextual information and consider multiple perspectives. A flexible, bespoke intervention was offered to pregnant women in intervention sites (delivered by a specialist maternity support worker, a specialist midwife, or a specialist Stop Smoking Wales pregnancy adviser) and compared with usual care delivered by the national stop smoking service. Routine data were collected from maternity records and the NHS Stop Smoking Wales service. The primary outcome was the proportion of smokers who engaged with the service. Power calculations showed that 1168 pregnant smokers were required to detect a 15% difference in the proportion of pregnant smokers engaged with smoking cessation services (5% type I error rate and 90% power).Findings2756 women were identified by midwifery staff as pregnant smokers (978 in intervention and 1778 in control sites). The proportion of smokers who engaged with the service was significantly higher across intervention sites than control sites. The highest proportion was observed in Health Board area 3, which employed a maternity support worker to support women to quit smoking, where 64 of 181 pregnant smokers (35%, 95% CI 29–43) set a quit date and attended at least one treatment session compared with just two of 227 in usual care (1%, 0–3). This model cost about £500 per engaged smoker. Qualitative findings highlighted the acceptability and feasibility of delivering the service models.InterpretationThe maternity support worker model is effective in engaging pregnant women with stop smoking services and has the potential to improve future health outcomes.FundingThe research received funding and support in kind from Public Health Wales NHS Trust and the Health Boards involved. Cwm Taf University Health Board's Research and Development department funded their element of the study.     

Smoking cessation

Smoking is a risk factor for the four leading causes of death in the United States, yet 48 million Americans--24% of the U.S. adult population--continue to smoke. Approximately 70% of people who smoke visit a physician each year, yet only half report ever being advised to quit smoking by their physician. Smoking cessation is difficult due to nicotine addiction and withdrawal symptoms. Expert groups such as the National Cancer Institute and the Agency for Health Care Policy and Research offer protocols for smoking cessation that primary care physicians can use in their office practice. Recent developments in the pharmacotherapy of smoking cessation has led the U.S. Public Health Service to update the practice guidelines for treating tobacco use and dependence. Pharmacotherapy, which includes nicotine replacement therapy, offers assistance to patients who want to stop smoking. However, the cost of pharmacotherapy may be a barrier for some. Other nonpharmacologic therapies, such as counseling, are also effective.     

A Review of Life-Course Familial and Lifestyle Factors of Smoking Initiation and Cessation

Smoking raises the risk of cardiovascular diseases in active and passive smokers throughout life. Taking a life-course approach, we reviewed current literature on the familial and lifestyle factors of smoking initiation and cessation. Single-parent and parental smoking are risk factors of smoking in young people, while smoking cessation of parents and family support predict quitting in both young and adult smokers. Results on the familial influences on relapses are limited and mixed in adolescents and adults. Regarding behavioral factors, poor eating habits and alcohol drinking would increase, and a high physical activity level would decrease, the likelihood of smoking in both adolescents and adults. Nutritional status of children improves with parental smoking cessation. In addition, disordered eating may hinder smoking cessation in women. Familial and behavioral factors interplay in their associations with smoking initiation and cessation in the life-course, which warranted further investigations for formulating better smoking prevention and cessation programs.     

Determinants of smoking and cessation in older women

BACKGROUND: although the benefits of quitting smoking even at an advanced age have been proved, few campaigns target the older population. The goals of this study were to analyse the characteristics of older women smokers help and support those wanting to quit. METHODS: we assessed the determinants of smoking cessation in a prospective cohort study performed in 7,609 older women. A questionnaire about smoking habits was sent to the 486 eligible smokers. Smoking dependence and smokers' readiness to quit was assessed. Participants who had quit smoking during follow-up were asked about their previous reasons for quitting and the methods used to quit. RESULTS: 372 women of the 424 (88%) responded to our questionnaire and were included. The most common reasons for smoking were relaxation, pleasure, and habit. Major obstacles to quitting smoking were 'no benefit to quitting at an advanced age', 'smoking few or "light" cigarettes yields no negative health consequences', and 'smoking does not increase osteoporotic risk'. During the 3-year follow-up period, 57 of the 372 (15%) women successfully quit smoking. Being an occasional smoker (OR=2.4) and reporting 'quitting is not difficult' (OR=3.7) were positively associated with having recently quit smoking. Only 11% of successful cessations were reported to have received physician advice. CONCLUSIONS: these data illustrate the specific smoking behaviour of older women, suggesting that cessation interventions ought to be tailored to these characteristics. Willingness to quit was associated with a low education level. The most frequent obstacles to quitting were all based on incorrect information.     

Evaluation of smoking cessation success in adults

BACKGROUND: Smoking is a preventable cause of increased morbidity and mortality. Therefore, interventions have been used to assist smokers in overcoming their addiction. The aim of the study was to describe factors associated with smoking cessation, in patients applied to our smoking cessation (SC) unit in 1999, in a prospective study. METHODS: Patients were followed-up during two years. Detailed medical history, Fagerstrom test, Hospital Anxiety and Depression (HAD) scale questionnaire, Motivation scale and replacement therapy were systematically recorded. RESULTS: Three hundred patients (58% men, 42% women) applied to the SC unit from January to December 1999. The mean age was 42 yrs old. They smoked in average 24 cig/d. Mean duration of smoking was 20 years. Fagerstrom score was 5.86 (min 0; max: 10). Patients seemed to be more anxious (score 9.6) than depressed (5.09), according to the HAD score. 79% of them received both psychosocial intervention, pharmacotherapy and nicotine replacement therapy. 66% of patients were followed-up (n=198). Two years later, the smoking cessation rate was 12% (n=36). Motivation, Fagerstrom and HAD scores were not associated with the quitting rate. Quitting rate was higher (25.9%) in patients who attempted to quit smoking for the first time than in others (19%). By contrast, the quitting rate was significantly associated with age (P=0.03). CONCLUSION: Success to quit smoking was positively associated with age, and negatively with alcohol dependence.     

Treatment of smoking cessation during pregnancy

Active and passive smoking during pregnancy is an important health problem. The majority of pregnant smoker women continue smoking during pregnancy. Because of the serious risks of tobacco to both mother and fetus, effective behavioral interventions and pharmacotherapy are needed to help pregnant smokers. Pharmacotherapy may useful smoking cessation in pregnancy, but may be the potential harmful effects of medication on the fetus. The very few studies exist that have studied the safety and efficacy of medications to treat pregnant smokers. The treatments for the use pregnancy smokers were summarized in this review.     

Does stage‐based smoking cessation advice in pregnancy result in long‐term quitters? 18‐month postpartum follow‐up of a randomized controlled trial

AIMS: To evaluate the effect on quitting smoking at 18 months postpartum of smoking cessation interventions based on the Transtheoretical Model (TTM) delivered in pregnancy compared to current standard care. It has been claimed that TTM-based interventions will continue to create quitters after the end of the intervention period. DESIGN: Cluster randomized trial. SETTING: Antenatal clinics in general practices in the West Midlands, UK. PARTICIPANTS: A total of 918 pregnant smokers originally enrolled in the trial, of which 393 women were followed-up at 18 months postpartum. INTERVENTIONS: One hundred general practices were randomized into the three trial arms. Midwives in these practices delivered three interventions: A (standard care), B (TTM-based self-help manuals) and C (TTM-based self-help manuals plus sessions with an interactive computer program giving individualized smoking cessation advice). MEASUREMENTS: Self-reported continuous and point prevalence abstinence since pregnancy. FINDINGS: When combined together, there was a slight and not significant benefit for both TTM arms compared to the control, with an odds ratio (OR) 95% confidence interval (CI) of 1.20 (0.29-4.88) for continuous abstinence. For point prevalence abstinence, the OR (95%CI) was 1.15 (0.66-2.03). Seven of the 54 (13%) women who had quit at the end of pregnancy were still quit 18 months later, and there was no evidence that the TTM-based interventions were superior in preventing relapse. CONCLUSIONS: The TTM-based interventions may have shown some evidence of a short-term benefit for quitting in pregnancy but no benefit relative to standard care when followed-up in the longer-term.     

Predictors of smoking cessation in patients admitted for acute coronary heart disease.

BACKGROUND: Smoking cessation is probably the most important single action after a coronary event. In order to increase the effectiveness of smoking cessation programs, it is important to have knowledge of the predictors of smoking cessation. Further, it is unknown whether smoking cessation programs have impact on these predictors. METHODS: Data were obtained from a randomized controlled trial of smoking cessation intervention in 240 smokers aged less than 76 years admitted for myocardial infarction, unstable angina, or cardiac bypass surgery. Baseline characteristics were prospectively recorded. Smoking cessation was determined by self report and biochemical verification at 12 months follow-up. RESULTS: In multivariate logistic regression analysis, a high level of nicotine addiction, low level of self-confidence in quitting and having previous coronary heart disease were significant negative predictors of smoking cessation at 12 months follow-up. Having previous coronary heart disease and a diagnosis other than acute myocardial infarction as a reason for admission were important negative predictors of abstinence in the usual care group, in contrast to the intervention group, although this did not reach a level of significance in the subgroup interaction analyses. A high level of nicotine addiction was a strong negative predictor in both groups. CONCLUSION: A high level of nicotine addiction is an important negative predictor of smoking cessation, even within an individualized smoking cessation program. Smoking cessation intervention seems to be especially effective in patients with previous coronary heart disease and in patients with unstable angina or coronary artery bypass surgery, compared to usual care.     

Benefits of smoking cessation

Smoking affects cardiovascular disease (CVD) risk through multiple biologic mechanisms, including inflammatory and hemostatic factors as well as the development of atheroma. Smoking cessation rapidly reduces the risk of CVD and death in a wide range of populations; previous studies may have under-estimated the benefits, as most rely on self-reported smoking status at one point in time only. Smoking cessation also considerably increases life expectancy and quality of life. Early studies were mostly confined to men in Western populations, but recent studies have confirmed that the risk of smoking (and benefits of quitting) appears similar in low-and middle-income countries and in women. Given the high prevalence of smoking and increasing incidence of CVD, the public health benefits from quitting are likely to be substantial in most parts of the world, and this should remain a top public health priority.     

Older adults and smoking.

This review supports the following conclusions regarding the benefits of smoking cessation in older adults: 1. Older smokers who quit have a reduced risk of death compared with current smokers within 1 to 2 years after quitting. Their overall risk of death approaches that of those who never smoked after 15 to 20 years of abstinence. 2. Smoking cessation in older adults markedly reduces the risks of coronary events and of cardiac deaths within 1 year of quitting, and risk continues to decline more gradually for many years. This is true for older adults both with and without a previous history of coronary disease and symptoms. 3. Risks of dying from several smoking-related cancers are reduced by quitting. Although the decline in risk may be more gradual for older than middle-aged adults, the benefits of cessation are apparent within 5 to 10 years of quitting. 4. Smoking cessation reduces the risk of COPD mortality after 10 to 15 years of abstinence in men and 5 to 10 years of abstinence in women. Within a shorter period of time, quitting reduces the prevalence of respiratory symptoms, slows the rate of decline in pulmonary function, and may reduce functional impairments and improve tolerance for exercise. 5. Smoking cessation may help slow osteoporosis and reduce the risk of hip fractures, but effects on rates of bone loss or subsequent risk of fracture have not yet been studied adequately. 6. Continued smoking in late life is associated with the development and progression of several major chronic conditions, loss of mobility, and poorer physical function. Former smokers appear to have higher levels of physical function and better quality of life than continuing smokers. Physicians and others should encourage older adults to stop smoking. Of course, not every older adult who quits will benefit in all, or indeed any, of these ways. Nevertheless, at the population level, the prospects are excellent that smoking cessation after age 65 will extend both the number of years of life and the quality of life.     

The Impact of Aversive Advice During Percutaneous Coronary Intervention on Smoking Cessation in Patients With Acute Coronary Syndrome

BackgroundSmoking cessation is important to prevent recurrence of acute coronary syndrome (ACS), but even in patients with ACS, smoking is hard to quit.ObjectivesThis study hypothesized that aversive advice during the percutaneous coronary intervention (PCI) procedure works effectively to promote smoking cessation in patients with ACS.MethodsThis study was conducted as a prospective, single-blinded, randomized controlled trial. A total of 66 patients were randomly assigned to an aversive advice group or a control group and instructed to visit the outpatient clinic 1, 4, and 24 weeks after discharge. In the aversive advice group, a physician who did not participate in the patient follow-up said the following 3 sentences to the patients during the PCI procedure: “Smoking caused your chest pain”; “If you do not stop smoking right now, this pain will come again”; and “The next time you feel this pain you will probably die.” All patients received usual advice on the importance of quitting smoking.ResultsAt 24 weeks after discharge, the smoking cessation rate was higher in the aversive advice group than in the control group. In a multivariable logistic regression analysis, after adjustment for age, smoking quantity, alcohol consumption, and disease severity, the result was maintained (odds ratio = 4.47, 95% confidence interval: 1.50 to 13.34).ConclusionsAversive advice during a PCI procedure is effective at smoking cessation in patients with ACS. A physician's attention and involvement during the PCI procedure improves the rate of smoking cessation in patients with ACS.     

Smoking and Diabetes: Sex and Gender Aspects and Their Effect on Vascular Diseases

Smoking and diabetes mellitus (DM) have been identified as 2 major cardiovascular risk factors for many years. In the field of cardiovascular diseases, considering sex differences, or gender differences, or both has become an essential element in moving toward equitable and quality health care. We reviewed the effect of sex or gender on the link between smoking and DM. The risk of type 2 DM due to smoking has been established in both sexes at the same level. As is the case in the general population, the prevalence of smoking in those with DM is higher in men than in women, although the decrease in smoking observed in recent years is more pronounced in men than in women. Regarding chronic DM complications, smoking is an independent risk factor for all-cause mortality, as well as macrovascular and microvascular complications, in both sexes. Nevertheless, in type 2 DM, the burden of smoking appears to be greater in women than in men for coronary heart disease morbidity, with women having a 50% greater risk of fatal coronary event. Women are more dependent to nicotine, cumulate psychosocial barriers to quitting smoking, and are more likely to gain weight, which might make it more difficult for them to quit smoking. Smoking cessation advice and treatments should take into account gender differences to improve the success and long-term maintenance of abstinence in people with and without DM. This might include interventions that address emotions and stress in women or designed to reach specific populations of men.     

Approach to Smoking Cessation in the Patient With Vascular Disease

In the patient with vascular disease, cigarette smoking is particularly perilous; the benefits of smoking cessation greatly exceed any risks associated with pharmacologic treatment. The patient with claudication is often uniquely motivated to quit smoking because 1) there is a chance that the leg pain will improve and 2) smoking cessation may prevent disease progression and thus invasive procedures. The first step toward success is a systematic approach with focus on the 5 A’s (Ask, Advise, Assess, Assist, and Arrange). Multiple clinical trials have demonstrated the efficacy of pharmacologic therapy for smoking cessation. The most effective medications available are bupropion and varenicline. If the patient is ready to quit, varenicline is typically first-line unless contraindicated. If the patient has concomitant signs or symptoms of depression, bupropion in combination with nicotine replacement therapy is preferred. In parallel with aggressive counseling and pharmacotherapy for smoking cessation, cardiovascular risk reduction is critical. Established atherosclerotic vascular disease (including peripheral artery disease, abdominal aortic aneurysm, or carotid artery disease) plus poorly controlled risk factors, including current smoking, place the patient in the “very high-risk” category, which favors reducing the low-density lipoprotein level to less than 70 mg/dL. The increased cardiovascular risk associated with smoking is tremendous, particularly in the vascular patient. Smoking cessation is critical, and no other health intervention offers such a large potential benefit.     

Women and smoking cessation: Challenges and opportunities

Tobacco smoking remains the most common preventable cause of death and disability in the United States. Although greatly decreased since the 1960s, the prevalence of smoking among women continues to be problematic because of the absolute prevalence and the continued increase in illnesses that take a long time to manifest (eg, lung cancer) in former smokers. Although no consensus exists, a number of research studies, meta-analyses, and reviews have concluded that quitting smoking appears to be more difficult for women than men. For example, in studies of medications to aid smoking cessation, women tend to have less success than men in maintaining longer-term cessation. Research has identified barriers and facilitators of smoking cessation specific to women and special populations of women (eg, minorities, pregnant women). There is a continued need for additional attention to the process of quitting smoking for women.     

Smoking Cessation Interventions and Older Adults

Older adults suffer a large proportion of the health consequences from smoking and can greatly benefit their health by quitting smoking. This article examines the current state of research and practice for older adults and smoking cessation interventions. For over 17 years, the health care literature has mandated that people of all ages be provided with smoking cessation interventions. However, smoking cessation interventions are offered to older adults at suboptimal rates. Nurses, especially those caring for clients in the inpatient setting, have an opportunity to provide smoking cessation interventions to older smokers. Recent research has shown that older smokers, particularly those hospitalized with cardiovascular disease, can quit at high rates when provided an intervention. Furthermore, use of nicotine replacement therapy has been shown to be safe and efficacious among older smokers with cardiovascular disease.